136 related articles for article (PubMed ID: 31922700)
1. Stakeholders' feedback on the proposed recommendations for updating the patented medicine prices review board (pmprb) budget impact analysis guidelines.
Foroutan N; Tarride JE; Xie F; Jameel B; Mills F; Levine M
J Popul Ther Clin Pharmacol; 2020 Jan; 27(1):e1-e24. PubMed ID: 31922700
[TBL] [Abstract][Full Text] [Related]
2. A Comparison of Pharmaceutical Budget Impact Analysis (BIA) Recommendations Amongst the Canadian Patented Medicine Prices Review Board (PMPRB), Public and Private Payers.
Foroutan N; Tarride JE; Xie F; Mills F; Levine M
Pharmacoecon Open; 2019 Dec; 3(4):437-451. PubMed ID: 31041614
[TBL] [Abstract][Full Text] [Related]
3. Guidelines for conducting pharmaceutical budget impact analyses for submission to public drug plans in Canada.
Marshall DA; Douglas PR; Drummond MF; Torrance GW; Macleod S; Manti O; Cheruvu L; Corvari R
Pharmacoeconomics; 2008; 26(6):477-95. PubMed ID: 18489199
[TBL] [Abstract][Full Text] [Related]
4. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.
Sullivan SD; Mauskopf JA; Augustovski F; Jaime Caro J; Lee KM; Minchin M; Orlewska E; Penna P; Rodriguez Barrios JM; Shau WY
Value Health; 2014; 17(1):5-14. PubMed ID: 24438712
[TBL] [Abstract][Full Text] [Related]
5. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis.
Mauskopf JA; Sullivan SD; Annemans L; Caro J; Mullins CD; Nuijten M; Orlewska E; Watkins J; Trueman P
Value Health; 2007; 10(5):336-47. PubMed ID: 17888098
[TBL] [Abstract][Full Text] [Related]
6. A methodological review of national and transnational pharmaceutical budget impact analysis guidelines for new drug submissions.
Foroutan N; Tarride JE; Xie F; Levine M
Clinicoecon Outcomes Res; 2018; 10():821-854. PubMed ID: 30538513
[TBL] [Abstract][Full Text] [Related]
7. The French National Authority for Health (HAS) Guidelines for Conducting Budget Impact Analyses (BIA).
Ghabri S; Autin E; Poullié AI; Josselin JM
Pharmacoeconomics; 2018 Apr; 36(4):407-417. PubMed ID: 29247437
[TBL] [Abstract][Full Text] [Related]
8. The impact of changing the reference countries on the list prices for patented medicines in Canada: A policy analysis.
Zhang W; Guh DP; Grootendorst P; Hollis A; Anis AH
Health Policy; 2024 Jun; 144():105064. PubMed ID: 38608459
[TBL] [Abstract][Full Text] [Related]
9. [HAS budget impact analysis guidelines: A new decision-making tool].
Ghabri S; Poullié AI; Autin E; Josselin JM
Sante Publique; 2017 Oct; 29(4):585-588. PubMed ID: 29034674
[TBL] [Abstract][Full Text] [Related]
10. Preapproval Information Exchange: Perspectives of U.S. Population Health Decision Makers on Preferences for Early Engagement with Investigational Therapies.
Brixner D; Woodward TC; Seifter N; Biskupiak J; Marciniak M; Neumann P; Oderda G
J Manag Care Spec Pharm; 2019 Feb; 25(2):164-173. PubMed ID: 30698089
[TBL] [Abstract][Full Text] [Related]
11. Generic competition in Canada.
Steele JW
Pharmacoeconomics; 1994 Nov; 6(5):480-2. PubMed ID: 10155276
[TBL] [Abstract][Full Text] [Related]
12. The impact of proposed price regulations on new patented medicine launches in Canada: a retrospective cohort study.
Zhang W; Sun H; Guh DP; Grootendorst P; Hollis A; Anis AH
CMAJ; 2024 May; 196(20):E691-E701. PubMed ID: 38802136
[TBL] [Abstract][Full Text] [Related]
13. Canadian status of "drugs to avoid" in 2017: a descriptive analysis.
Lexchin J
CMAJ Open; 2018; 6(3):E430-E435. PubMed ID: 30266781
[TBL] [Abstract][Full Text] [Related]
14. Treatment Access, Health Economics, and the Wave of a Magic Wand.
Stewart DJ; Bradford JP; Batist G
Curr Oncol; 2022 Feb; 29(2):1176-1189. PubMed ID: 35200599
[TBL] [Abstract][Full Text] [Related]
15. The Canadian Patented Medicine Prices Review Board. New rules and new status.
Shulman SR
Pharmacoeconomics; 1994; 6 Suppl 1():71-9. PubMed ID: 10155589
[TBL] [Abstract][Full Text] [Related]
16. What is the budget impact of a new treatment or new health technology arriving on the market?
Dervaux B; Le Fur C; Dubois S; Josseran A;
Therapie; 2017 Feb; 72(1):93-103. PubMed ID: 28159198
[TBL] [Abstract][Full Text] [Related]
17. Financial Characteristics of Outcomes-Based Agreements: What Do Canadian Public Payers and Pharmaceutical Manufacturers Prefer?
Wills A; Mitha A
Value Health; 2024 Mar; 27(3):340-346. PubMed ID: 38154595
[TBL] [Abstract][Full Text] [Related]
18. Impact of a financial risk-sharing scheme on budget-impact estimations: a game-theoretic approach.
Gavious A; Greenberg D; Hammerman A; Segev E
Eur J Health Econ; 2014 Jun; 15(5):553-61. PubMed ID: 24326947
[TBL] [Abstract][Full Text] [Related]
19. A Methodological Review of US Budget-Impact Models for New Drugs.
Mauskopf J; Earnshaw S
Pharmacoeconomics; 2016 Nov; 34(11):1111-1131. PubMed ID: 27334107
[TBL] [Abstract][Full Text] [Related]
20. A critical systematic review of budget impact analyses on drugs in the EU countries.
van de Vooren K; Duranti S; Curto A; Garattini L
Appl Health Econ Health Policy; 2014 Feb; 12(1):33-40. PubMed ID: 24158922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
